Park J, Chung S, Matsuo Y, Nakamura Y. Development of small molecular compounds targeting cancer stem cells. Medchemcomm. 2017;8:73-80 pubmed publisher
..In addition, we will discuss recently developed small molecules for these protein targets, which have shown remarkable anti-tumor efficacies in several preclinical studies. ..
Ikeda Y, Park J, Miyamoto T, Takamatsu N, Kato T, Iwasa A, et al
. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. Clin Cancer Res. 2016;22:6110-6117 pubmed
..Our results demonstrated the clinical significance of high TOPK expression and potential of TOPK inhibitors to treat ovarian cancer. Clin Cancer Res; 22(24); 6110-7. ©2016 AACR. ..
Yap K, Kiyotani K, Tamura K, Antic T, Jang M, Montoya M, et al
. Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin Cancer Res. 2014;20:6605-17 pubmed publisher
..Additional mechanistic investigation into the previously undiscovered role of UNC5C in bladder cancer is warranted. ..
Matsuda T, Leisegang M, Park J, Ren L, Kato T, Ikeda Y, et al
. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin Cancer Res. 2018;24:5357-5367 pubmed publisher
..i>Clin Cancer Res; 24(21); 5357-67. ©2018 AACR See related commentary by Anczurowski and Hirano, p. 5195. ..
Deng Z, Matsuda K, Tanikawa C, Lin J, Furukawa Y, Hamamoto R, et al
. Late Cornified Envelope Group I, a novel target of p53, regulates PRMT5 activity. Neoplasia. 2014;16:656-64 pubmed publisher
..Our data suggest that LCE1 is a novel p53 downstream target that can be directly transactivated by p53 and is likely to have tumor suppressor functions through modulation of the PRMT5 activity. ..
Matsuo Y, Park J, Miyamoto T, Yamamoto S, Hisada S, Alachkar H, et al
. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014;6:259ra145 pubmed publisher
..Our results suggest that the inhibition of TOPK activity may be a viable therapeutic option for the treatment of various human cancers. ..
Zewde M, Kiyotani K, Park J, Fang H, Yap K, Yew P, et al
. The era of immunogenomics/immunopharmacogenomics. J Hum Genet. 2018;63:865-875 pubmed publisher
..Here we report the potential of deep sequencing of T-cell and B-cell receptors in capturing the molecular contribution of the immune system, which we believe plays critical roles in the pathogenesis of various human diseases. ..
Mutonga M, Tamura K, Malnassy G, Fulton N, de Albuquerque A, Hamamoto R, et al
. Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL). Transl Oncol. 2015;8:368-75 pubmed publisher
..On the other hand, SUV39H2 overexpression made cells more resistant to chemotherapy. We conclude that SUV39H2 is a promising therapeutic target and further investigation of this therapeutic approach in ALL is warranted. ..
Matsuda K, Takahashi A, Middlebrooks C, Obara W, Nasu Y, Inoue K, et al
. Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population. Hum Mol Genet. 2015;24:1177-84 pubmed publisher
..Our finding implies the crucial roles of genetic variations on the chemically associated development of bladder cancer. ..